[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pasithea Therapeutics Corp (KTTA)

Pasithea Therapeutics Corp (KTTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,590
  • Shares Outstanding, K 24,940
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,430 K
  • EBIT $ -22 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.28
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.08
  • Most Recent Earnings $-0.12 on 05/15/26
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 1
  • High Estimate $-0.16
  • Low Estimate $-0.16
  • Prior Year $-0.66
  • Growth Rate Est. (year over year) +75.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5701 +0.96%
on 06/04/26
0.8150 -29.37%
on 05/15/26
-0.2197 (-27.62%)
since 05/08/26
3-Month
0.5397 +6.65%
on 04/01/26
0.9627 -40.21%
on 05/04/26
-0.2209 (-27.73%)
since 03/06/26
52-Week
0.2810 +104.84%
on 11/21/25
2.0600 -72.06%
on 11/28/25
-0.3102 (-35.02%)
since 06/06/25

Most Recent Stories

More News
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET – – Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments,...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomarker-driven...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin...

KTTA : 0.5756 (-1.61%)
KTTAW : 0.0056 (+14.29%)

Business Summary

Pasithea Therapeutics Corp. is a biotechnology company. It focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. is based in MIAMI BEACH, Fla.

See More

Key Turning Points

3rd Resistance Point 0.6188
2nd Resistance Point 0.6084
1st Resistance Point 0.5920
Last Price 0.5756
1st Support Level 0.5652
2nd Support Level 0.5548
3rd Support Level 0.5384

See More

52-Week High 2.0600
Fibonacci 61.8% 1.3804
Fibonacci 50% 1.1705
Fibonacci 38.2% 0.9606
Last Price 0.5756
52-Week Low 0.2810

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.